Phase I trial of the androgen receptor modulator CR1447 in breast cancer
Endocrine Connections Sep 04, 2017
Zweifel M, et al. – This study was undertaken to investigate the safety of the dose of CR1447, administered as an ointment, for Phase II. It was concluded that CR1447 administered transdermally as an ointment is well tolerated and appears to have single–agent activity in heavily pretreated ER–positive/HER2–negative breast cancer patients. In addition, the recommended phase II dose is 400 mg/day.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
